Pear Therapeutics is proud to have a group of investors that represent the unique composition of the company, spanning biotech, technology and pharma. The company has closed three rounds of private fundraising to-date: most recently, a $64 million Series C in January 2019; a $50 million Series B in December 2017; and a $20 million Series A in February 2016.
Pear Investors and Partners
Focus on expansion and scale
